BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc

Bullboard Posts

Comment by peteswimon Apr 04, 2011 10:52am

205 Views

Post# 18381295

RE: Can Someone post L2 ?

# Orders	Shares	Bid	Ask	Shares	# Orders
1	17500	0.145	0.150	149500	4
2	77000	0.140	0.155	125000	7
3	78000	0.135	0.160	44500	4
9	96000	0.130	0.165	7500	2
5	161000	0.125	0.170	5000	1